Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE vs CALCIPOTRIENE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.
Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.
Moderate to severe pain relief; combinations are used to reduce abuse potential.
Plaque psoriasis (FDA-approved),Psoriasis of the scalp (FDA-approved),Chronic plaque psoriasis (off-label),Psoriatic nails (off-label),Ichthyosis (off-label),Vitiligo (off-label)
Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.
Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.
Pentazocine has an elimination half-life of 2-3 hours in healthy adults, which may be prolonged in patients with hepatic impairment. Naloxone has a terminal half-life of 0.5-1.5 hours in adults, with a rapid decline in plasma levels; the short half-life limits its duration of opioid antagonism.
The terminal elimination half-life of calcipotriene is approximately 5–6 hours following topical application. Systemic clearance is rapid due to extensive hepatic metabolism, leading to minimal accumulation.
Pentazocine is metabolized primarily by hepatic conjugation (glucuronidation) and oxidation via CYP2C19 and CYP2D6; naloxone is extensively metabolized by the liver, primarily via glucuronidation (UGT2B7).
Calcipotriene undergoes extensive hepatic metabolism via cytochrome P450 enzymes (mainly CYP3A4, CYP2D6, and CYP1A2) to inactive metabolites, which are excreted in feces and urine.
Pentazocine is primarily metabolized in the liver and excreted in urine as conjugates of glucuronide and sulfate, with about 60% of a dose excreted renally within 24 hours as metabolites and unchanged drug (less than 5% unchanged). Naloxone undergoes extensive hepatic metabolism to naloxone-3-glucuronide, which is excreted renally; approximately 50% of a dose is excreted as conjugates in urine within 6 hours.
Calcipotriene is rapidly metabolized in the liver to inactive metabolites; less than 1% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 70% of the administered dose, primarily as metabolites, with about 16% excreted in urine.
Pentazocine: Approximately 35-65% bound to plasma proteins (mainly albumin). Naloxone: Approximately 32-45% bound to plasma proteins (mainly albumin).
Calcipotriene is approximately 94% bound to plasma proteins, primarily albumin.
Pentazocine: Vd ~2-3 L/kg, indicating extensive tissue distribution. Naloxone: Vd ~2-3 L/kg, also indicating wide distribution.
Due to extensive tissue binding and lipophilicity, the apparent volume of distribution (Vd) is estimated to be >5 L/kg, indicating extensive distribution into tissues.
Oral pentazocine: 20-30% due to first-pass metabolism. Intramuscular pentazocine: 100%. Subcutaneous pentazocine: 100%. Oral naloxone: <2% due to extensive first-pass metabolism. Intramuscular and subcutaneous naloxone: 100%. Intravenous: 100% for both.
Systemic bioavailability after topical application is less than 1% when applied to normal skin (0.5–1.0%) and up to 5–6% when applied to psoriatic plaques due to increased permeability.
GFR 30-50 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Administer every 12 hours or consider alternative.
No adjustment required due to minimal systemic absorption.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend interval; Child-Pugh Class C: Avoid use.
No adjustment required due to minimal systemic absorption.
Not recommended for children under 12 years. For older children (≥12 years): Pentazocine 50 mg (with naloxone 0.5 mg) orally every 3-4 hours as needed; maximum 6 tablets daily.
Children ≥2 years: apply 0.005% cream or ointment once daily, not exceeding 50 g per week. Safety and efficacy in children <2 years not established.
Initiate with half the usual adult dose (one-half tablet) and titrate carefully due to increased sensitivity and risk of respiratory depression.
No specific geriatric adjustment; use caution due to increased risk of skin irritation and potential for reduced renal function.
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of life-threatening respiratory depression when used with benzodiazepines or other CNS depressants.
None.
Respiratory depression; hypotension; increased intracranial pressure; seizure risk (pentazocine); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; interaction with MAOIs; risk of dependence and withdrawal; gastrointestinal obstruction; impaired renal or hepatic function; head injury.
Hypercalcemia: Avoid exceeding recommended dose; monitor serum calcium, urine calcium, and serum phosphate in patients with renal impairment or when used with other vitamin D products.,Local skin reactions: Irritation, itching, erythema, burning; discontinue if severe.,Photosensitivity: Avoid excessive exposure to sunlight or artificial UV light.,Use on face, groin, or axillae may increase irritation.,Not recommended in patients with known disorders of calcium metabolism.
Hypersensitivity to pentazocine or naloxone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; patients receiving MAOIs or within 14 days.
Hypercalcemia or evidence of vitamin D toxicity,Hypersensitivity to calcipotriene or any component of the formulation,Use on face, eyes, or mucous membranes
No specific food interactions are reported for this combination. However, grapefruit juice may theoretically affect metabolism via CYP3A4 (pentazocine is metabolized by CYP3A4), but clinical significance is unknown. Advise patients to maintain a consistent diet.
No specific food interactions. Maintain adequate calcium and vitamin D intake as per normal dietary recommendations. Avoid high-dose calcium or vitamin D supplements unless prescribed, as additive hypercalcemic risk.
Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Third trimester: Chronic use may cause fetal dependence; neonatal withdrawal syndrome reported. High doses near term may cause neonatal respiratory depression.
Pregnancy Category C. Systemic exposure is minimal with topical use, but animal studies have shown fetal abnormalities at high doses. No adequate human studies; risk cannot be ruled out. First trimester: insufficient data; second and third trimesters: avoid unless clearly needed. Topical application at recommended doses is unlikely to cause harm, but caution advised.
Pentazocine is excreted in breast milk in small amounts (estimated relative infant dose <3%). Naloxone is poorly bioavailable orally. Generally considered compatible with breastfeeding; monitor infant for sedation or poor feeding. M/P ratio for pentazocine is approximately 1.0.
Excretion into breast milk unknown. Topical calcipotriene has low systemic absorption; however, avoid application to breast area to prevent infant ingestion. M/P ratio not available. Use with caution in nursing mothers only if clearly needed.
No established dose adjustments for pregnancy; however, pharmacokinetic changes (increased volume of distribution, enhanced clearance) may require higher or more frequent doses of pentazocine for adequate analgesia. Use lowest effective dose and shortest duration.
No dose adjustment required for topical use as systemic absorption is minimal. However, limit use to small areas to minimize cumulative exposure. No pharmacokinetic studies in pregnancy indicate need for dose change.
Naloxone in this fixed-dose combination is included to deter opioid abuse by reversing euphoria. The pentazocine component is a mixed agonist-antagonist opioid; naloxone has poor oral bioavailability but becomes active parenterally, precipitating withdrawal in opioid-dependent individuals. Use with caution in patients with impaired renal or hepatic function. Monitor for respiratory depression, especially in opioid-naive patients, as pentazocine alone can cause respiratory depression.
Calcipotriene is a synthetic vitamin D3 analog used primarily for plaque psoriasis. It works by inhibiting keratinocyte proliferation and promoting differentiation. Avoid use on the face, intertriginous areas, and anogenital region due to irritation risk. Maximum weekly dose should not exceed 100 g to avoid hypercalcemia. Use with caution in patients with renal impairment or known hypercalcemia. Combination with topical corticosteroids can enhance efficacy and reduce irritation.
Take exactly as prescribed; do not crush or inject tablets, as injected naloxone can cause severe withdrawal in opioid-dependent individuals.,This medication contains naloxone to discourage misuse; injection will cause withdrawal symptoms.,Report any signs of withdrawal (e.g., nausea, vomiting, sweating, agitation) or breathing difficulty.,Avoid alcohol and other central nervous system depressants as they increase risk of respiratory depression.,Do not use with other opioids unless directed, as effects are unpredictable.,Keep out of reach of children; accidental ingestion may cause severe respiratory depression.
Apply a thin layer to affected areas only, avoiding healthy skin.,Wash hands after application unless treating hands.,Do not use on the face, groin, or skin folds unless specifically directed.,Do not exceed 100 grams per week to avoid side effects.,Avoid excessive sun exposure or tanning beds during treatment.,Inform your doctor if you experience signs of high calcium: nausea, vomiting, constipation, muscle weakness.,Use exactly as prescribed; do not use occlusive dressings unless instructed.,May cause local skin irritation; report severe reactions to your doctor.
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE vs CALCIPOTRIENE, answered by our medical review team.
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.. CALCIPOTRIENE is a Vitamin D Analog that works by Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE and CALCIPOTRIENE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is: Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.. The standard adult dose of CALCIPOTRIENE is: Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE and CALCIPOTRIENE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Thi. CALCIPOTRIENE is classified as Category C. Pregnancy Category C. Systemic exposure is minimal with topical use, but animal studies have shown fetal abnormalities at high doses. No adequate human studies; risk cannot be rule. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.